This is a working overview of amino acid sequence, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-16 and is reviewed periodically as new material appears.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
== History == The sequence of human GM-CSF was first identified in 1985 and soon three recominbant human GM-CSFs were produced, one in bacteria, one in mammalian cells, and one in yeast; Immunex developed GM-CSF manufactured in yeast into Leukine. Clinical trials of sargramostim were initiated in 1987; in that same year it was administered to six people as part of a compassionate-use protocol for the victims of cesium irradiation from the Goiânia accident. It was approved by the FDA in March 1991, under the brand name Leukine for acceleration of white blood cell recovery following autologous bone marrow transplantation in people with non-Hodgkin's lymphoma, acute lymphocytic leukemia, or Hodgkin's disease. In November 1996, the FDA also approved sargramostim for treatment of fungal infections and replenishment of white blood cells following chemotherapy. A liquid formulation was approved in 1995. Immunex was acquired by Amgen in 2002. As part of the acquisition, Leukine was spun off to Berlex, which became Bayer HealthCare in 2007. In January 2008, Bayer informed healthcare professionals of the market withdrawal of the current liquid formulation of sargramostim. The liquid formulation was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change that was made to the formulation around April 2007 to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates had not been observed with the use of lyophilized sargramostim.
=== Acatalasia === Acatalasia is a condition caused by homozygous mutations in CAT, resulting in a lack of catalase. Symptoms are mild and include oral ulcers. A heterozygous CAT mutation results in lower, but still present catalase.
The system uses frequency-hopping spread spectrum transmission, in which successive data packets are transmitted in a pseudorandom order on one of 79 1 MHz Bluetooth channels between 2.4 and 2.83 GHz in the ISM band. This allows Bluetooth networks to operate in the presence of noise, other wireless devices and other Bluetooth networks using the same frequencies, since the chance of another device attempting to transmit on the same frequency at the same time as the Bluetooth modem is low. In the case of such a "collision", the Bluetooth modem just retransmits the data packet on another frequency. Packet radio – a long-distance peer-to-peer wireless ad-hoc network in which data packets are exchanged between computer-controlled radio modems (transmitter/receivers) called nodes, which may be separated by miles, and maybe mobile. Each node only communicates with neighboring nodes, so packets of data are passed from node to node until they reach their destination using the X.25 network protocol. Packet radio systems are used to a limited degree by commercial telecommunications companies and by the amateur radio community. Text messaging (texting) – this is a service on cell phones, allowing a user to type a short alphanumeric message and send it to another phone number, and the text is displayed on the recipient's phone screen. It is based on the Short Message Service (SMS) which transmits using spare bandwidth on the control radio channel used by cell phones to handle background functions like dialing and cell handoffs.
=== Ferdinand Schwarzwald === Ferdinand Schwarzwald (Nico Rogner) is the CFO of family-owned Austrian bank IBN Bauer, and a director on the board of Tender, in which his bank has a 6% stake. He backs Whitney's vision for pivoting the company away from pornography and gambling clients and into banking, and cautions Whitney that his co-founder and CEO Jonah Atterbury is "not a serious person", contributing to Jonah's eventual removal from the company. Ferdinand later helps Whitney and new Tender CEO Henry Muck execute a merger with IBN Bauer, traveling with them to Vienna to assuage the concerns of family heir Moritz-Hunter Bauer. He and Whitney also procure a billion-dollar investment from Al-Mi'raj Pierpoint during the release of Tender's banking app. Ferdinand is later revealed to be Whitney's handler on behalf of Russian foreign intelligence, having been recruited years ago by Cozy Bear (the hacker group affiliated with the FSB and SVR) and installed as IBN Bauer's CFO after stealing client lists that Russia could use as leverage. Amid public revelations of Tender's fraudulent profits out of Africa, Ferdinand warns Whitney that their narrative must remain intact, and implies that the Russians can assassinate anyone who goes "off-message". Ferdinand and fixer Dez Watkins later catch Whitney trying to disappear via New York and intercept him, forcing him to proceed with a hostile takeover bid for Pierpoint as it would represent a valuable "data set" for Russia.
== Treatment == Management of chronic granulomatous disease revolves around two goals: 1) diagnose the disease early so that antibiotic prophylaxis can be given to keep an infection from occurring, and 2) educate the patient about his or her condition so that prompt treatment can be given if an infection occurs.
Sources: en.wikipedia.org
== Background == Mays was born in Reynoldsville, West Virginia, in 1975. She was a United States Army West Virginia National Guard veteran who served from November 2000 to April 2001 and again from February 2003 to May 2004, when she deployed to Iraq and Kuwait with the 1092nd Engineer Battalion. Prior to beginning her employment as a nursing assistant at the Louis A. Johnson Veterans Medical Center, Mays had worked as a corrections officer at the West Virginia Department of Corrections at North Central Regional Jail in Greenwood, West Virginia, between 2005 and 2012. In 2013, Mays was one of several defendants in a lawsuit that was brought by an inmate incarcerated at the jail who alleged that he had been repeatedly beaten by Mays and other correction officers. The lawsuit was dismissed on summary judgment. Mays was a longtime member of Monroe Chapel United Methodist, a small church approximately twenty minutes outside Clarksburg in Lost Creek.
This identification was later corrected to 258Lr, as later work proved that 257Lr did not have the properties detected, but 258Lr did. This was considered at the time to be convincing proof of synthesis of element 103: while the mass assignment was less certain and proved to be mistaken, it did not affect the arguments in favor of element 103 having been synthesized. Scientists at Joint Institute for Nuclear Research in Dubna (then in the Soviet Union) raised several criticisms: all but one were answered adequately. The exception was that 252Cf was the most common isotope in the target, and in the reactions with 10B, 258Lr could only have been produced by emitting four neutrons, and emitting three neutrons was expected to be much less likely than emitting four or five. This would lead to a narrow yield curve, not the broad one reported by the Berkeley team. A possible explanation was that there was a low number of events attributed to element 103. This was an important intermediate step to the unquestioned discovery of element 103, although the evidence was not completely convincing. The Berkeley team proposed the name "lawrencium" with symbol "Lw", after Ernest Lawrence, inventor of the cyclotron. The IUPAC Commission on Nomenclature of Inorganic Chemistry accepted the name, but changed the symbol to "Lr". This acceptance of the discovery was later characterized as being hasty by the Dubna team.
Bate-Smith, E. C. (Sep 1954). "Leuco-Anthocyanins". Biochem. J. 58 (1): 122–125. doi:10.1042/bj0580122. PMC 1269852. PMID 13198862. Pecket, R.C. Constituents of Leaf Extracts ... , New Phytologist 1959 Oct; 58(2) (retrieved 27 sept 2010 http://onlinelibrary.wiley.com/doi/10.1111/j.1469-8137.1959.tb05350.x/pdf ) Stecher, G. and Bonn, G. K., Phytochemical Analysis, Chromatography, Elsevier Science, E. Heftmann (ed), Amsterdam, pp. 1050. ISBN 0-444-51108-3 (2004) (retrieved via google books 9/27/2010)
He noted their unusual physiological characteristics. On 7 June, Humboldt, Bonpland, and Sotto began the final 300 miles of their journey. As the river widened, the population grew more diverse. They reached Angostura, now Ciudad Bolivar, on 13 June, completing a pioneering exploration of 1,500 miles between the Orinoco and Amazon basins. The expedition measured positions of more than 50 locations, collected magnetic data, and amassed 12,000 plant specimens, many new to science. Humboldt credited Bonpland’s energy and courage. The climate damaged a significant portion of their botanical collection. Shortly after arrival in Angostura, Humboldt, Bonpland, and a servant became seriously ill, likely with typhoid. Humboldt recovered quickly, but Bonpland’s illness was severe and slow to resolve. After a month, Bonpland was fit enough for the journey across the Llanos to the coast. Their return was delayed by a privateer, but British naval intervention rescued them. By late August 1800, they reached Cumana, concluding the first phase of their South American expedition after nearly a year away.
Sources: en.wikipedia.org
=== Non-cardiac conditions === The distinction between cardiac and non-cardiac conditions is somewhat artificial; the conditions listed below are not primary heart diseases, but they exert indirect effects on the heart muscle. Other conditions that directly or indirectly lead to heart muscle damage and death can also increase troponin levels, such as kidney failure. Cardiac troponins are increased in around 40% of patients with critical illnesses such as sepsis. There is an increased risk of mortality and length of stay in the intensive-care unit in these patients. In severe gastrointestinal bleeding, there can also be a mismatch between oxygen demand and supply of the myocardium.
However, though the Huks fought the Japanese, they also "tried to thwart United States Army Forces in the Far East guerrillas", "therefore, they were considered disloyal and were not accorded U.S. recognition or benefits at the end of the war."
== Structure == The human epididymis is situated posterior and somewhat lateral to the testis. The epididymis is invested completely by the tunica vaginalis (which is continuous with the tunica vaginalis covering the testis). The epididymis can be divided into three main regions:
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.